SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026

▤ Summary

SEED Therapeutics announced ASCO 2026 data on ST-01156, its oral RBM39 molecular glue degrader now in first-in-human Phase 1 testing. The company says the study is designed to establish safety, pharmacokinetics, target engagement, and the recommended Phase 2 dose. It also outlined planned expansion cohorts in Ewing sarcoma, hepatocellular carcinoma, KRAS-mutant cancers, and other RBM39-dependent tumors. Preclinical findings showed tumor regression in several models, supporting the drug’s broader oncology potential and SEED’s clinical development strategy.

▦ Linked Companies